Search research articles
Contact Us
Filters
Showing results (381-390 of 588) with videos related to
Page
of 59
Sort By:
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity
|
February 12, 2024
Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials
Wenjia Yang, Han Wu, Xiaoling Cai, et al.
Diabetes, Obesity & Metabolism
|
April 13, 2023
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J Aronne, et al.
Value in Health Regional Issues
|
November 13, 2018
Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach
Volker Foos, Ke Wang, Phil McEwan, et al.
The Lancet. Diabetes & Endocrinology
|
June 7, 2025
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Liana K Billings, Francesco Andreozzi, Marie Frederiksen, et al.
Scientific Reports
|
May 24, 2019
The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
Xiaoling Cai, Dayi Hu, Changyu Pan, et al.
Diabetes, Obesity & Metabolism
|
November 17, 2017
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial
Yingli Chen, Xiaomin Liu, Quanmin Li, et al.
Diabetes, Obesity & Metabolism
|
April 4, 2023
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials
Vanita R Aroda, Juan Pablo Frias, Linong Ji, et al.
Pharmaceutical Medicine
|
April 4, 2024
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings
Feng Sun, Alexander Bedenkov, Bi-Cheng Liu, et al.
Iscience
|
September 25, 2024
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Yuchen Guo, Chu Lin, Xiaoling Cai, et al.
Journal of Evidence-Based Medicine
|
June 18, 2022
Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
Fang Zhang, Linong Ji, Tianpei Hong, et al.
Page
of 59
Search research articles
Search
Showing results (381-390 of 588) with videos related to
Sort By:
Page
of 59
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity
|
February 12, 2024
Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials
Wenjia Yang, Han Wu, Xiaoling Cai, et al.
Diabetes, Obesity & Metabolism
|
April 13, 2023
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J Aronne, et al.
Value in Health Regional Issues
|
November 13, 2018
Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach
Volker Foos, Ke Wang, Phil McEwan, et al.
The Lancet. Diabetes & Endocrinology
|
June 7, 2025
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Liana K Billings, Francesco Andreozzi, Marie Frederiksen, et al.
Scientific Reports
|
May 24, 2019
The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
Xiaoling Cai, Dayi Hu, Changyu Pan, et al.
Diabetes, Obesity & Metabolism
|
November 17, 2017
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial
Yingli Chen, Xiaomin Liu, Quanmin Li, et al.
Diabetes, Obesity & Metabolism
|
April 4, 2023
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials
Vanita R Aroda, Juan Pablo Frias, Linong Ji, et al.
Pharmaceutical Medicine
|
April 4, 2024
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings
Feng Sun, Alexander Bedenkov, Bi-Cheng Liu, et al.
Iscience
|
September 25, 2024
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Yuchen Guo, Chu Lin, Xiaoling Cai, et al.
Journal of Evidence-Based Medicine
|
June 18, 2022
Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
Fang Zhang, Linong Ji, Tianpei Hong, et al.
Page
of 59